![Michael Houghton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Houghton
Directeur/Membre du Conseil chez
ASSEMBLY BIOSCIENCES, INC.
Fortune : 107 683 $ au 31/08/2026
Profil
Michael Houghton is currently Chairman-Virology & Professor at the University of Alberta since 2010.
Dr. Houghton is Director at the Li Ka Shing Institute of Virology.
Dr. Houghton is Independent Director at Assembly Biosciences, Inc. since 2021.
Dr. Houghton is Director at Achlys, Inc., Prophysis, Inc., Aurora Vaccines, Inc., Heka Therapeutics, Inc., and Egerio, Inc. Formerly, Dr. Houghton was Vice President-Hepatitis C & Virology Research at Novartis Vaccines & Diagnostics, Inc. Dr. Houghton was Chief Scientific Officer at Epiphany Biosciences, Inc. from 2007 to 2009.
Dr. Houghton was Professor at the University of Alberta.
Dr. Houghton completed undergraduate studies at the University of East Anglia and earned a doctorate from King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/06/2026 | 3 202 ( 0,02 % ) | 107 683 $ | 31/08/2026 |
Postes actifs de Michael Houghton
| Sociétés | Poste | Début |
|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Directeur/Membre du Conseil | 19/07/2021 |
Li Ka Shing Institute of Virology
 Li Ka Shing Institute of Virology Miscellaneous Commercial ServicesCommercial Services Engages in conducting research to develops hepatitis vaccines and antiviral therapies | Directeur/Membre du Conseil | - |
University of Alberta
 University of Alberta Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2010 |
Achlys, Inc. | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Houghton
| Sociétés | Poste | Fin |
|---|---|---|
Epiphany Biosciences, Inc.
 Epiphany Biosciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutic products and diagnostic technologies | Directeur Technique/Scientifique/R&D | 01/01/2009 |
University of Alberta
University of Alberta Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | - |
Formation de Michael Houghton
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Epiphany Biosciences, Inc.
Epiphany Biosciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutic products and diagnostic technologies | Health Technology |
University of Alberta
University of Alberta Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of East Anglia
 University of East Anglia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Li Ka Shing Institute of Virology
Li Ka Shing Institute of Virology Miscellaneous Commercial ServicesCommercial Services Engages in conducting research to develops hepatitis vaccines and antiviral therapies | Commercial Services |
Assembly Biosciences, Inc.
 Assembly Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of products for infectious diseases | Health Technology |
Achlys, Inc. |
